Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Many Pharmacists Don't Explain Generics to Patients: Survey
July 7, 2008
- Introduce Reference Price System to Promote Use of Generics: Council
July 7, 2008
- GENERICS NEWS IN BRIEF
July 7, 2008
- Late-Stage Consultation Fee to Be Frozen
July 7, 2008
- Addition of Zetia More Effective Than Doubling Dose of Statins: Prof. Yamada
July 7, 2008
- FPMAJ Presents NHI Pricing System Reform Proposal to Chuikyo
July 7, 2008
- Only 20% of General Citizens Aware of HbA1c
July 7, 2008
- FDA Extends Review Period for Prasugrel: Daiichi Sankyo, Eli Lilly
July 7, 2008
- Nexavar Well Tolerated in Japanese Renal Cancer Patients
July 7, 2008
- REGULATORY NEWS IN BRIEF
July 7, 2008
- PPIs Drugs of Choice for Dyspepsia Symptoms: J-FOCUS Study
July 7, 2008
- DSP Quickly Expands R&D Pipeline in the Field of Diabetes
July 7, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 7, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 7, 2008
- Bayer Yakuhin to Achieve \200 Bil. Sales in 5 Years
July 7, 2008
- Physician-led Study of Talc to Begin Soon
July 7, 2008
- Daiichi Sankyo to Work Out Collaboration Plans Country by Country: Mr Shoda
July 7, 2008
- Sawai Aims at Achieving \100 Bil. Sales before Any Other Generic Company in Japan
July 7, 2008
- Otsuka Pharm. to Be Reorganized under New Holding Company
July 7, 2008
- Blopress Best-Selling Ethical Drug 4 Years in a Row
July 7, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…